Filippo Cademartiri: Plaque Burden Is the Dominant Determinant of Long-Term Coronary Risk Beyond Stenosis
Filippo Cademartiri, Consultant Advanced Cardiovascular Imaging at UPMC Salvator Mundi International Hospital, shared on LinkedIn about a recent article by Ruurt A. Jukema et al, adding:
“Stenosis vs Plaque: We’ve been looking at the wrong winner.
Tackling stenosis above all does not make biological sense.
This study tackles a fundamental question in coronary artery disease:
- What really predicts outcomes over time?
- Is it how narrow the artery is… or how much disease is actually there?
Key message
The prognostic value of coronary disease is not static.
Early on: stenosis matters (flow limitation drives events)
Over time: plaque burden becomes dominant
Translation:
The more disease you carry, the more it matters than how tight a single lesion looks.
Why this is disruptive
For decades, cardiology has been built around:
- % stenosis
- ischemia
- revascularization decisions
But this paper reinforces something deeper:
Atherosclerosis is a diffuse, dynamic disease — not a focal narrowing problem.
The real shift
Plaque burden is:
- More stable as a biomarker
- More reflective of total disease biology
- More predictive in the long term
While stenosis?
- Fluctuates
- Is lesion-specific
- May miss the bigger picture
Clinical implications
If you focus only on stenosis:
- You treat lesions.
If you focus on plaque burden:
- You treat the disease.
That’s a completely different strategy.
Bottom line
We are moving from:
‘How tight is the blockage?’
to
‘How much disease is there overall?’
And that shift changes everything:
- Risk stratification
- Treatment intensity
- Prevention strategies
Final thought
- The artery doesn’t fail because of one stenosis.
- It fails because of the total plaque ecosystem.
And that’s where the future of imaging – and cardiology – is heading.”
Title: The time-varying prognostic value of stenosis and plaque burden in coronary artery disease
Authors: Ruurt A. Jukema, Teemu Maaniitty, Nick S. Nurmohamed, Pieter G. Raijmakers, Roel Hoek, Roel S. Driessen, R. Nils Planken, Jos Twisk, Pim van der Harst, Maarten J. Cramer, Antti Saraste, Paul Knaapen, Juhani Knuuti, Ibrahim Danad

Stay updated on all scientific advances with Hemostasis Today.
-
Jul 17, 2026, 04:28Redefining Thromboprophylaxis in Multiple Myeloma: Early VTE Emerges as the Critical Therapeutic Challenge
-
Jul 16, 2026, 20:25Ilham Benzidia: Leaving ISTH 2026 With New Ideas and New Collaborations
-
Jul 16, 2026, 20:23Eman Hassan: A Fantastic Platelets and Megakaryocytes Session at ISTH 2026
-
Jul 16, 2026, 20:22Sankara Nelson Noah II: Investigating the Temporal Dynamics of Platelet – Leukocyte Interactions in Early Sepsis
-
Jul 16, 2026, 20:20Joseph Pierre Aboumsallem: Paris Certainly Delivered This Week, and Not Just Because of the Heat
-
Jul 16, 2026, 19:53Louise St. Germain Bannon: The End of Congress, the Beginning of New Collaborations
-
Jul 16, 2026, 19:18Steve Humphreys: Learning From the Leading Experts at ISTH 2026
-
Jul 16, 2026, 19:02Kellie Machlus: Where Science Meets Friendship at ISTH 2026
-
Jul 16, 2026, 18:51Aaron Paul Kithcart: When Clinical Research Comes Together at ISTH 2026